EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review

Jin Li, Yu-Bo Liang, Qing-Bo Wang, Wan-Ling Luo, Xing-Ming Chen, Yawhan Lakang, Zi-Sheng Yang, Jin-Xiang Zuo, Yu-Kai Li, Zhiwei Li, Yong Peng, Yong-Bin Chen, Yang Ke

Liver Cancer · 2025-10-31 · 1-20

DOI: 10.1159/000549355 ↗
AbstractBibliografische Angaben

Abstract

Background: Rechallenge with immune checkpoint inhibitors (ICIs) has recently emerged as a potential therapeutic strategy for patients with hepatocellular carcinoma (HCC) who discontinue initial immunotherapy due to disease progression, immune-related adverse events (irAEs), or treatment completion. However, there are no standardized rechallenge regimen, patient indications, and few studies on its mechanism. Summary: This review provided a comprehensive, up-to-date summary on the clinical evidence, treatment regimens, patient characteristics, and biological rationale underlying ICI rechallenge for HCC patients. Current studies have identified four main rechallenge strategies according to the combinations of agents used in the initial and rechallenge treatments, most of which involve targeted therapy combined with anti-PD-L1 or dual ICIs. Across published studies, ICI rechallenge has shown variable but notable antitumor activity with an acceptable safety profile. Clinical benefits appear to be more frequently observed in HCC patients with preserved liver function, age

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →